Glaucoma - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 298
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G6ABB164C82EN
Leaflet:

Download PDF Leaflet

Glaucoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Glaucoma - Pipeline Review, H2 2016’, provides an overview of the Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Glaucoma
  • The report reviews pipeline therapeutics for Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Glaucoma therapeutics and enlists all their major and minor projects
  • The report assesses Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Glaucoma
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Glaucoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Glaucoma Overview
Therapeutics Development
Glaucoma - Therapeutics under Development by Companies
Glaucoma - Therapeutics under Investigation by Universities/Institutes
Glaucoma - Pipeline Products Glance
Glaucoma - Products under Development by Companies
Glaucoma - Products under Investigation by Universities/Institutes
Glaucoma - Companies Involved in Therapeutics Development
Glaucoma - Therapeutics Assessment
Drug Profiles
Glaucoma - Dormant Projects
Glaucoma - Discontinued Products
Glaucoma - Product Development Milestones
Appendix 284

LIST OF TABLES

Number of Products under Development for Glaucoma, H2 2016
Number of Products under Development for Glaucoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016
Glaucoma - Pipeline by AC Immune SA, H2 2016
Glaucoma - Pipeline by Acadia Pharmaceuticals Inc., H2 2016
Glaucoma - Pipeline by Advanced Refractive Technologies, Inc., H2 2016
Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016
Glaucoma - Pipeline by Allergan Plc, H2 2016
Glaucoma - Pipeline by Altacor Limited, H2 2016
Glaucoma - Pipeline by Amakem NV, H2 2016
Glaucoma - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Glaucoma - Pipeline by Amgen Inc., H2 2016
Glaucoma - Pipeline by Astellas Pharma Inc., H2 2016
Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016
Glaucoma - Pipeline by BioAxone BioSciences, Inc., H2 2016
Glaucoma - Pipeline by Bionure Farma, S.L., H2 2016
Glaucoma - Pipeline by Coronis Partners Ltd., H2 2016
Glaucoma - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016
Glaucoma - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Glaucoma - Pipeline by Gilead Sciences, Inc., H2 2016
Glaucoma - Pipeline by Glaukos Corporation, H2 2016
Glaucoma - Pipeline by Graybug Vision Inc, H2 2016
Glaucoma - Pipeline by Handok Inc., H2 2016
Glaucoma - Pipeline by HitGen LTD, H2 2016
Glaucoma - Pipeline by Icon Bioscience, Inc., H2 2016
Glaucoma - Pipeline by ID Pharma Co., Ltd., H2 2016
Glaucoma - Pipeline by InMed Pharmaceuticals Inc., H2 2016
Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016
Glaucoma - Pipeline by InSite Vision Incorporated, H2 2016
Glaucoma - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016
Glaucoma - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016
Glaucoma - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016
Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016
Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016
Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
Glaucoma - Pipeline by Merck & Co., Inc., H2 2016
Glaucoma - Pipeline by Nemus Bioscience, Inc., H2 2016
Glaucoma - Pipeline by NicOx S.A., H2 2016
Glaucoma - Pipeline by NoNO, Inc., H2 2016
Glaucoma - Pipeline by Novaliq GmbH, H2 2016
Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016
Glaucoma - Pipeline by Oculis ehf, H2 2016
Glaucoma - Pipeline by Ohr Pharmaceutical Inc., H2 2016
Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016
Glaucoma - Pipeline by Profarma, H2 2016
Glaucoma - Pipeline by pSivida Corp., H2 2016
Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
Glaucoma - Pipeline by Quethera Limited, H2 2016
Glaucoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Glaucoma - Pipeline by Sanofi, H2 2016
Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
Glaucoma - Pipeline by Shire Plc, H2 2016
Glaucoma - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
Glaucoma - Pipeline by Sylentis S.A.U., H2 2016
Glaucoma - Pipeline by ViSci Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Glaucoma - Dormant Projects, H2 2016
Glaucoma - Dormant Projects (Contd..1), H2 2016
Glaucoma - Dormant Projects (Contd..2), H2 2016
Glaucoma - Dormant Projects (Contd..3), H2 2016
Glaucoma - Dormant Projects (Contd..4), H2 2016
Glaucoma - Dormant Projects (Contd..5), H2 2016
Glaucoma - Dormant Projects (Contd..6), H2 2016
Glaucoma - Dormant Projects (Contd..7), H2 2016
Glaucoma - Discontinued Products, H2 2016
Glaucoma - Discontinued Products (Contd..1), H2 2016 285

LIST OF FIGURES

Number of Products under Development for Glaucoma, H2 2016
Number of Products under Development for Glaucoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


NeoStem, Inc. - Product Pipeline Review - 2014 US$ 1,200.00 Dec, 2014 · 45 pages
DNAVEC Corporation - Product Pipeline Review - 2015 US$ 1,200.00 May, 2015 · 25 pages
Burns - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 107 pages

Ask Your Question

Glaucoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: